Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
MAGEB4 Biologics Sequence Review Report 2026: Melanoma-associated antigen B4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB2 Biologics Sequence Review Report 2026: Melanoma-associated antigen B2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEB18 Biologics Sequence Review Report 2026: Melanoma-associated antigen B18 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEB18 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA8 Biologics Sequence Review Report 2026: Melanoma-associated antigen 8 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA6 Biologics Sequence Review Report 2026: Melanoma-associated antigen 6 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA4 Biologics Sequence Review Report 2026: Melanoma-associated antigen 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA3 Biologics Sequence Review Report 2026: Melanoma-associated antigen 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA2 Biologics Sequence Review Report 2026: Melanoma-associated antigen 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA12 Biologics Sequence Review Report 2026: Melanoma-associated antigen 12 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA11 Biologics Sequence Review Report 2026: Melanoma-associated antigen 11 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
MAGEA1 Biologics Sequence Review Report 2026: Melanoma-associated antigen 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MAGEA1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LY96 Biologics Sequence Review Report 2026: Lymphocyte antigen 96 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LY96 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
213
214
215
216
217
>>
2260
>